Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
CNS Spectr. 2005 Nov;10(11 Suppl 18):17-21.

Rationalizing therapeutic approaches in Alzheimer's disease.

Author information

  • 1Department of Psychiatry and Human Behavior, Saint Louis University Health Science Center, Wohl Clinic, 1221 South Grand Boulevard, St. Louis, MO 63104, USA. grossbgt@slu.edu

Abstract

Deficits in cholinergic and glutamatergic neurotransmission have been linked to the symptomatology of Alzheimer's disease, and current therapies for Alzheimer's, including cholinesterase inhibitors (ChEIs) and the N-methyl-d-aspartate receptor antagonist memantine, have been developed to compensate for these deficits. This article reviews the results of clinical trials involving agents approved by the United States Food and Drug Administration for use in the treatment of Alzheimer's disease (namely, ChEIs for mild to moderate Alzheimer's and memantine for moderate to severe Alzheimer's). In particular, the efficacy of current monotherapy strategies in the treatment of cognitive and functional symptoms of Alzheimer's disease will be addressed. In addition, data from a clinical trial examining the use of a ChEI in combination with memantine will also be discussed, as it has been hypothesized that ChEIs and memantine may offer synergistic benefits due to their distinct mechanisms of action.

PMID:
16273026
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk